588 related articles for article (PubMed ID: 28006059)
21. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
[TBL] [Abstract][Full Text] [Related]
22. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
23. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
25. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
26. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
27. Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer.
Pajares B; Perez-Villa L; Trigo JM; Toledo MD; Alvarez M; Jimenez B; Medina JA; de Luque V; Jerez JM; Alba E
Clin Transl Oncol; 2014 Apr; 16(4):418-24. PubMed ID: 24193865
[TBL] [Abstract][Full Text] [Related]
28. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
29. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
Bauman JE; Austin MC; Schmidt R; Kurland BF; Vaezi A; Hayes DN; Mendez E; Parvathaneni U; Chai X; Sampath S; Martins RG
Br J Cancer; 2013 Oct; 109(8):2096-105. PubMed ID: 24064970
[TBL] [Abstract][Full Text] [Related]
30. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
31. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.
Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS
J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822
[TBL] [Abstract][Full Text] [Related]
32. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
[TBL] [Abstract][Full Text] [Related]
34. TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO).
Grünwald V; Keilholz U; Boehm A; Guntinas-Lichius O; Hennemann B; Schmoll HJ; Ivanyi P; Abbas M; Lehmann U; Koch A; Karch A; Zörner A; Gauler TC
Ann Oncol; 2015 Mar; 26(3):561-7. PubMed ID: 25527417
[TBL] [Abstract][Full Text] [Related]
35. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer.
Caudell JJ; Torres-Saavedra PA; Rosenthal DI; Axelrod RS; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; El-Naggar AK; Konski AA; Echevarria MI; Dunlap NE; Shenouda G; Singh AK; Beitler JJ; Garsa A; Bonner JA; Garden AS; Algan O; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):533-543. PubMed ID: 36549347
[TBL] [Abstract][Full Text] [Related]
37. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
38. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
39. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
[TBL] [Abstract][Full Text] [Related]
40. Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck.
Riaz N; Sherman E; Koutcher L; Shapiro L; Katabi N; Zhang Z; Shi W; Fury M; Wong R; Wolden S; Rao S; Lee N
Am J Clin Oncol; 2016 Feb; 39(1):27-31. PubMed ID: 24401670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
